IRVINE, Calif.--(BUSINESS WIRE)--CardiAQ Valve Technologies (CardiAQ), a leader in the field of Transcatheter Mitral Valve Implantation (“TMVI”), announced today that the European Patent Office Legal Division issued a temporary stay of further proceedings in Neovasc’s pending European patent application covering TMVI technology. This action comes as the initial result of the lawsuit filed late June 2014 in Germany by CardiAQ against Neovasc.
Help employers find you! Check out all the jobs and post your resume.
